These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 22266779)
1. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779 [TBL] [Abstract][Full Text] [Related]
2. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats. Liu X; Cheong J; Ding X; Deshmukh G Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459 [TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030 [TBL] [Abstract][Full Text] [Related]
4. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters. Hoque MT; Kis O; De Rosa MF; Bendayan R Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630 [TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323 [TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939 [TBL] [Abstract][Full Text] [Related]
7. Use of the cassette-dosing approach to assess brain penetration in drug discovery. Liu X; Ding X; Deshmukh G; Liederer BM; Hop CE Drug Metab Dispos; 2012 May; 40(5):963-9. PubMed ID: 22328585 [TBL] [Abstract][Full Text] [Related]
8. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535 [TBL] [Abstract][Full Text] [Related]
9. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039 [TBL] [Abstract][Full Text] [Related]
10. Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats. Huang L; Li X; Roberts J; Janosky B; Lin MH Xenobiotica; 2015; 45(6):547-55. PubMed ID: 25539457 [TBL] [Abstract][Full Text] [Related]
11. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters. Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297 [TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806 [TBL] [Abstract][Full Text] [Related]
13. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats. Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619 [TBL] [Abstract][Full Text] [Related]
14. Characterization of efflux transporters involved in distribution and disposition of apixaban. Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458 [TBL] [Abstract][Full Text] [Related]
15. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171 [TBL] [Abstract][Full Text] [Related]
16. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates. Braun C; Sakamoto A; Fuchs H; Ishiguro N; Suzuki S; Cui Y; Klinder K; Watanabe M; Terasaki T; Sauer A Mol Pharm; 2017 Oct; 14(10):3436-3447. PubMed ID: 28880093 [TBL] [Abstract][Full Text] [Related]
17. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437 [TBL] [Abstract][Full Text] [Related]
18. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. An G; Gallegos J; Morris ME Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040 [TBL] [Abstract][Full Text] [Related]
19. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Ose A; Kusuhara H; Endo C; Tohyama K; Miyajima M; Kitamura S; Sugiyama Y Drug Metab Dispos; 2010 Jan; 38(1):168-76. PubMed ID: 19833843 [TBL] [Abstract][Full Text] [Related]
20. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Zhang S; Wang X; Sagawa K; Morris ME Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]